Elaine Wirrell, MD
Epilepsy · Rochester, MNNPI 1255526430
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $124,875 of the $159,698 with a category attached, or 78.2%. 18 manufacturers reported payments, led by Biocodex, Inc. at 25.2% of the total. 2025 is the largest year on record at $55,484, 2.9 times the $19,162 reported in 2019.
Across 111 payments — averaging $1438.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocodex, Inc.$40K
- Acadia Pharmaceuticals Inc$23K
- UCB SA$17K
- Jazz Pharmaceuticals Inc.$16K
- Biomarin Pharmaceutical Inc.$12K
- Neurocrine Biosciences, Inc.$11K
- plus $40K from 12 others
Across 124 payments — averaging $4635.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$183K
- Immedica Pharma US, Inc.$110K
- H. Lundbeck A S$90K
- Takeda Pharmaceuticals U.S.A., Inc.$79K
- SK Life Science, Inc.$77K
- Zogenix Inc.$34K
- plus $3K from 1 others
What the payments were for
- Consulting fees$124,87578%
- Speaking & faculty fees$16,55010%
- Travel & lodging$15,46510%
- Food & beverage$2,3841%
- Education$4240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocodex, Inc. | 19 | $40,237 |
| Acadia Pharmaceuticals Inc | 13 | $23,000 |
| UCB SA | 7 | $17,029 |
| Jazz Pharmaceuticals Inc. | 8 | $16,013 |
| Biomarin Pharmaceutical Inc. | 20 | $12,469 |
| Neurocrine Biosciences, Inc. | 7 | $10,525 |
| UCB, Inc. | 17 | $9,434 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $6,175 |
| Amicus Therapeutics, Inc. | 6 | $4,400 |
| Greenwich Biosciences, Inc. | 1 | $4,320 |
| Mallinckrodt Enterprises LLC | 4 | $4,271 |
| Eisai Inc. | 1 | $3,240 |
| Eisai CO., LTD. | 1 | $2,400 |
| Zogenix Inc. | 2 | $2,400 |
| Immedica Pharma US, Inc. | 1 | $1,515 |
| Aquestive Therapeutics, Inc. | 1 | $1,020 |
| Hikma Pharmaceuticals USA | 1 | $1,000 |
| Cipla USA Inc. | 1 | $250 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few epilepsy providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other epilepsy in Rochester
- Katherine NickelsRochester$23K
- Gregory WorrellRochester$11K
- Brian LundstromRochester$9K
- Kelsey SmithRochester$3K
- Christopher SanfilippoRochester$1K
- David BurkholderRochester$714
- Nicholas GreggRochester$312
- Anthony FineRochester$231
- Gregory CascinoRochester$203
- Hicham DabajaRochester$195
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.